Allergan lets insults fly at hostile suitor Valeant and its 'Wizard of Oz' buyout bid

Save

The Valeant/Allergan takeover battle was already pretty heated, with the Canadian pharma taking its latest rejected offer to Allergan shareholders. But it's getting hotter, thanks to some layoffs, an exec exit, a lawsuit, a litany of barbs from Allergan–and yet another Valeant conference call.